Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ZIVO 
Zivo Bioscience Inc (ZIVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: ZIVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 352.97% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 46.47M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.18 | 52 Weeks Range 7.01 - 22.15 | Updated Date 12/2/2025 |
52 Weeks Range 7.01 - 22.15 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1551.76% |
Management Effectiveness
Return on Assets (TTM) -1001.91% | Return on Equity (TTM) -3956.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45014684 | Price to Sales(TTM) 222.31 |
Enterprise Value 45014684 | Price to Sales(TTM) 222.31 | ||
Enterprise Value to Revenue 215.36 | Enterprise Value to EBITDA -3.01 | Shares Outstanding 3888595 | Shares Floating 1389784 |
Shares Outstanding 3888595 | Shares Floating 1389784 | ||
Percent Insiders 63.49 | Percent Institutions 0.11 |
Upturn AI SWOT
Zivo Bioscience Inc
Company Overview
History and Background
Zivo Bioscience Inc. was founded in 2006. It is a biotechnology company engaged in the research and development of therapeutic and nutritional candidates derived from algae.
Core Business Areas
- Human Health: Development of algae-based therapeutic candidates for inflammatory and immunological conditions.
- Animal Health: Development of algae-based nutritional ingredients for improved animal health and performance.
Leadership and Structure
Andrew Dahl is the Chief Executive Officer. The company operates with a typical corporate structure involving a board of directors and functional departments.
Top Products and Market Share
Key Offerings
- DHAVAlga: A proprietary algae strain being developed for both human and animal health applications. Market share data specific to DHAVAlga is not readily available, as the product is still in development. Competitors in the algae-based products market include companies developing omega-3 supplements and alternative protein sources.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, rapid technological advancements, and significant regulatory oversight. Algae-based products are gaining traction as a sustainable source of nutrition and therapeutics.
Positioning
Zivo Bioscience Inc. is positioned as an innovator in the algae-based biotechnology space, focusing on proprietary strains and novel applications. Their competitive advantage lies in their patented technology and vertically integrated business model
Total Addressable Market (TAM)
The global market for algae-based products is estimated in the billions of dollars and growing. Zivo Bioscience Inc. is positioned to capture a portion of this TAM with its proprietary technology and targeted applications.
Upturn SWOT Analysis
Strengths
- Proprietary algae strain (DHAVAlga)
- Vertically integrated business model
- Focus on novel applications in human and animal health
- Issued Patents
Weaknesses
- Limited financial resources
- Product development risk
- Lack of established market presence
- Reliance on regulatory approvals
Opportunities
- Growing demand for sustainable nutrition sources
- Expanding applications of algae-based products
- Potential partnerships with established players
- Increasing funding for biotechnology research
Threats
- Competition from established biotechnology companies
- Regulatory hurdles
- Price sensitivity in the commodity market
- Unforeseen technical challenges
Competitors and Market Share
Key Competitors
- DSM (DSM.AS)
- Corbion (CRBN.AS)
- Qualitas Health (Privately Held)
Competitive Landscape
Zivo Bioscience Inc faces competition from larger, more established players with greater financial resources. Their advantages lie in their proprietary technology and focus on specialized applications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not provided in this response.
Future Projections: Future projections are not provided in this response.
Recent Initiatives: Recent initiatives include advancements in DHAVAlga formulation and ongoing clinical trials for human health applications. The company is also actively seeking partnerships and collaborations.
Summary
Zivo Bioscience Inc. is a biotechnology company focused on algae-based products. Their proprietary technology offers potential advantages. However, the company faces financial constraints and competition. Successful product development and commercialization are critical for future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data may be outdated or incomplete. Consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zivo Bioscience Inc
Exchange NASDAQ | Headquaters Troy, MI, United States | ||
IPO Launch date 2012-09-24 | President, CEO & Chairman of the Board Mr. John Bernard Payne | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.zivobioscience.com |
Full time employees 7 | Website https://www.zivobioscience.com | ||
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.